Biophytis (EPA:ALBPS)

PRESS RELEASE

published on 07/22/2024 at 08:12, 1 year 6 months ago

Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia
Biophytis signs partnership contracts with local agents in Asia to accelerate deployment of BIO101 drug candidate, targeting age-related diseases in key markets like Japan and China

Biophytis Partnership Asia Age-related Diseases BIO101
BRIEF

published on 07/22/2024 at 07:05, 1 year 6 months ago

Biophytis Signs Contracts with Local Agents in Asia

Biotechnology Pharmaceutical Partnerships Age-related Diseases Asia Market
REGULATED PRESS RELEASE

published on 07/22/2024 at 07:00, 1 year 6 months ago

Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia
Biophytis implements partnership strategy in Asia with new contracts to advance drug candidate BIO101 in Japan, South Korea, China, and Southeast Asia

Biophytis Asia Contracts Partnership Strategy Drug Candidate BIO101
BRIEF

published on 07/11/2024 at 08:18, 1 year 6 months ago

Biophytis Obtains IND Approval from FDA for Phase 2 Obesity Study

Biophytis FDA Approval Phase 2 Clinical Trial BIO101 Obesity Study
PRESS RELEASE

published on 07/11/2024 at 08:13, 1 year 6 months ago

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity
Biophytis receives FDA IND approval for phase 2 OBA study in obesity with BIO101 (20-hydroxyecdysone), focusing on muscle strength improvement. Study led by renowned expert Marc-André Cornier

FDA Biophytis Obesity IND Approval OBA Study
BRIEF

published on 07/11/2024 at 07:06, 1 year 6 months ago

Biophytis Receives FDA IND Approval for Phase 2 Obesity Study

Biophytis FDA Approval Phase 2 Study BIO101 Obesity
REGULATED PRESS RELEASE

published on 07/11/2024 at 07:01, 1 year 6 months ago

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity
Biophytis obtains FDA approval to start phase 2 OBA study in obesity with BIO101 (20-hydroxyecdysone), focusing on muscle strength improvement. Study led by Prof. Marc-André Cornier to start mid-2024 in the USA

Biophytis FDA Approval Obesity Treatment BIO101 Phase 2 OBA Study
BRIEF

published on 07/01/2024 at 07:05, 1 year 6 months ago

Biophytis Presents Promising Phase 2-3 COVA Study Results on Severe Covid-19 at WCID in Paris

Biophytis COVID-19 Clinical Trials COVA Study Infectious Diseases
PRESS RELEASE

published on 07/01/2024 at 07:00, 1 year 6 months ago

Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris
Biophytis presents positive results from Phase 2-3 COVA study for severe Covid-19 at WCID Paris. Bio101 shows significant efficacy and safety in reducing risk of respiratory failure and death

Biophytis COVID-19 Positive Results Phase 2-3 COVA Study Respiratory Failure
REGULATED PRESS RELEASE

published on 07/01/2024 at 07:00, 1 year 6 months ago

Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris
Biophytis presented positive results of its Phase 2-3 COVA study for severe Covid-19 at WCID in Paris, showing reduction in respiratory failure and death rates

Biophytis COVID-19 Positive Results Phase 2-3 COVA Study

Published on 01/31/2026 at 03:15, 7 hours 6 minutes ago

Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 8 hours 1 minute ago

Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 8 hours 41 minutes ago

Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/31/2026 at 00:00, 10 hours 21 minutes ago

BE Resources Announces Private Placement
Published on 01/30/2026 at 23:00, 11 hours 21 minutes ago

Avidian Gold Corp. Announces Director Resignation

View all ACCESSWIRE

Published on 01/31/2026 at 02:45, 7 hours 35 minutes ago

CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 12 hours 21 minutes ago

Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 14 hours 10 minutes ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 20:09, 14 hours 11 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 20:07, 14 hours 13 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches

View all EQS

Published on 01/30/2026 at 17:45, 16 hours 36 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 1 day 2 hours ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day 16 hours ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 16 hours ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 16 hours ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE

News